Literature DB >> 2890514

Drug treatment of phobias. Efficacy and optimum use.

A P Levin1, M R Liebowitz.   

Abstract

In the last decade anxiety disorders have been the focus of intensive research in the psychiatric community, resulting in a rapid growth in our understanding of these illnesses. Diagnostic, biological, and psychopharmacological investigations have revealed important distinctions among these disorders which enable the clinician to make well-informed therapeutic choices and frequently ameliorate or even eliminate anxiety symptoms and related phobic behaviour. The principles of treatment can be simply stated: 1. Careful diagnostic evaluation through history and exclusion of medical and psychiatric conditions which mimic anxiety disorders. 2. Treatment selection based on diagnosis and formulation with the patient of the goals and expected outcome of pharmacotherapy. 3. Systematic application of each drug treatment in sufficient dosage and for an adequate duration permitting progression to the next agent when results are not optimal. 4. Addition of non-pharmacological interventions, usually behavioural therapy, to decrease phobic behaviour. 5. Development of a maintenance or discontinuation strategy tailored to the needs of the patient.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890514     DOI: 10.2165/00003495-198734040-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  18 in total

1.  DELINEATION OF TWO DRUG-RESPONSIVE ANXIETY SYNDROMES.

Authors:  D F KLEIN
Journal:  Psychopharmacologia       Date:  1964-06-08

2.  Benzodiazepine overuse-misuse.

Authors:  R I Shader; D J Greenblatt
Journal:  J Clin Psychopharmacol       Date:  1984-06       Impact factor: 3.153

3.  Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.

Authors:  J P Feighner; J Herbstein; N Damlouji
Journal:  J Clin Psychiatry       Date:  1985-06       Impact factor: 4.384

Review 4.  Combined MAOI-tricyclic antidepressant treatment: a reevaluation.

Authors:  K White; G Simpson
Journal:  J Clin Psychopharmacol       Date:  1981-09       Impact factor: 3.153

5.  Phenelzine v imipramine in atypical depression. A preliminary report.

Authors:  M R Liebowitz; F M Quitkin; J W Stewart; P J McGrath; W Harrison; J Rabkin; E Tricamo; J S Markowitz; D F Klein
Journal:  Arch Gen Psychiatry       Date:  1984-07

6.  Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment.

Authors:  D V Sheehan; J H Coleman; D J Greenblatt; K J Jones; P H Levine; P J Orsulak; M Peterson; J J Schildkraut; E Uzogara; D Watkins
Journal:  J Clin Psychopharmacol       Date:  1984-04       Impact factor: 3.153

7.  D-amphetamine in obsessive-compulsive disorder.

Authors:  T R Insel; J A Hamilton; L B Guttmacher; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

8.  Hypoglycemia and panic attacks.

Authors:  J M Gorman; J M Martinez; M R Liebowitz; A J Fyer; D F Klein
Journal:  Am J Psychiatry       Date:  1984-01       Impact factor: 18.112

9.  Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial.

Authors:  P Thorén; M Asberg; B Cronholm; L Jörnestedt; L Träskman
Journal:  Arch Gen Psychiatry       Date:  1980-11

10.  Effect of acute beta-adrenergic blockade on lactate-induced panic.

Authors:  J M Gorman; G F Levy; M R Liebowitz; P McGrath; I L Appleby; D J Dillon; S O Davies; D F Klein
Journal:  Arch Gen Psychiatry       Date:  1983-10
View more
  1 in total

1.  Sodium valproate and clonazepam for treatment-resistant panic disorder.

Authors:  A Ontiveros; R Fontaine
Journal:  J Psychiatry Neurosci       Date:  1992-06       Impact factor: 6.186

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.